CA2688589A1 - Intradermal hpv peptide vaccination - Google Patents
Intradermal hpv peptide vaccination Download PDFInfo
- Publication number
- CA2688589A1 CA2688589A1 CA002688589A CA2688589A CA2688589A1 CA 2688589 A1 CA2688589 A1 CA 2688589A1 CA 002688589 A CA002688589 A CA 002688589A CA 2688589 A CA2688589 A CA 2688589A CA 2688589 A1 CA2688589 A1 CA 2688589A1
- Authority
- CA
- Canada
- Prior art keywords
- hpv
- medicament
- peptide
- cells
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 163
- 238000002255 vaccination Methods 0.000 title description 21
- 239000003814 drug Substances 0.000 claims abstract description 65
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 55
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 60
- 206010028980 Neoplasm Diseases 0.000 claims description 51
- 239000002671 adjuvant Substances 0.000 claims description 42
- 201000011510 cancer Diseases 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 238000007920 subcutaneous administration Methods 0.000 claims description 14
- 230000003902 lesion Effects 0.000 claims description 13
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 10
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 10
- 201000010881 cervical cancer Diseases 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 5
- 102100032937 CD40 ligand Human genes 0.000 claims description 4
- 230000001270 agonistic effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 206010061424 Anal cancer Diseases 0.000 claims description 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 3
- 108010029697 CD40 Ligand Proteins 0.000 claims description 3
- -1 CpG nucleic acid Chemical class 0.000 claims description 3
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
- 206010034299 Penile cancer Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 201000011165 anus cancer Diseases 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims 11
- 241000701806 Human papillomavirus Species 0.000 description 100
- 210000001744 T-lymphocyte Anatomy 0.000 description 72
- 210000003491 skin Anatomy 0.000 description 54
- 238000012360 testing method Methods 0.000 description 51
- 206010040914 Skin reaction Diseases 0.000 description 50
- 230000035483 skin reaction Effects 0.000 description 50
- 231100000430 skin reaction Toxicity 0.000 description 50
- 241000341655 Human papillomavirus type 16 Species 0.000 description 48
- 239000000427 antigen Substances 0.000 description 44
- 108091007433 antigens Proteins 0.000 description 44
- 102000036639 antigens Human genes 0.000 description 44
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 28
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 20
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 230000036039 immunity Effects 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 102000004127 Cytokines Human genes 0.000 description 16
- 108090000695 Cytokines Proteins 0.000 description 16
- 230000005867 T cell response Effects 0.000 description 16
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 230000002163 immunogen Effects 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 230000028993 immune response Effects 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 13
- 206010008263 Cervical dysplasia Diseases 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 12
- 230000003213 activating effect Effects 0.000 description 12
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 12
- 230000004913 activation Effects 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 210000000612 antigen-presenting cell Anatomy 0.000 description 10
- 102000002689 Toll-like receptor Human genes 0.000 description 9
- 108020000411 Toll-like receptor Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000009803 radical hysterectomy Methods 0.000 description 9
- 208000019065 cervical carcinoma Diseases 0.000 description 8
- 210000002443 helper t lymphocyte Anatomy 0.000 description 8
- 208000021145 human papilloma virus infection Diseases 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000009826 neoplastic cell growth Effects 0.000 description 7
- 230000005951 type IV hypersensitivity Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000043129 MHC class I family Human genes 0.000 description 6
- 108091054437 MHC class I family Proteins 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 210000001821 langerhans cell Anatomy 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 238000011510 Elispot assay Methods 0.000 description 5
- 241000701646 Kappapapillomavirus 2 Species 0.000 description 5
- 108091054438 MHC class II family Proteins 0.000 description 5
- 241001631646 Papillomaviridae Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 210000004392 genitalia Anatomy 0.000 description 5
- 210000003071 memory t lymphocyte Anatomy 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000009696 proliferative response Effects 0.000 description 5
- 238000007388 punch biopsy Methods 0.000 description 5
- 238000000729 Fisher's exact test Methods 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102000000743 Interleukin-5 Human genes 0.000 description 4
- 108010002616 Interleukin-5 Proteins 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 206010051999 Anogenital dysplasia Diseases 0.000 description 3
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 101000952099 Homo sapiens Antiviral innate immune response receptor RIG-I Proteins 0.000 description 3
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 3
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 description 3
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 3
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 3
- 206010046905 Vaginal dysplasia Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000018777 Vulvar intraepithelial neoplasia Diseases 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 201000003565 cervix uteri carcinoma in situ Diseases 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 108091008819 oncoproteins Proteins 0.000 description 3
- 102000027450 oncoproteins Human genes 0.000 description 3
- 208000003154 papilloma Diseases 0.000 description 3
- 229960002566 papillomavirus vaccine Drugs 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000007390 skin biopsy Methods 0.000 description 3
- QCVIFBRTTLMEOV-FUKQNADPSA-M sodium;(2r)-2-[[(2r)-2-[[(2s)-2-[[(2s,6r)-2,6-dimethylpiperidine-1-carbonyl]amino]-4,4-dimethylpentanoyl]amino]-3-(1-methoxycarbonylindol-3-yl)propanoyl]amino]hexanoate Chemical compound [Na+].N([C@@H](CC(C)(C)C)C(=O)N[C@H](CC=1C2=CC=CC=C2N(C(=O)OC)C=1)C(=O)N[C@H](CCCC)C([O-])=O)C(=O)N1[C@@H](C)CCC[C@H]1C QCVIFBRTTLMEOV-FUKQNADPSA-M 0.000 description 3
- 208000022159 squamous carcinoma in situ Diseases 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229960001005 tuberculin Drugs 0.000 description 3
- 208000022625 uterine cervix carcinoma in situ Diseases 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 102000010180 Endothelin receptor Human genes 0.000 description 2
- 108050001739 Endothelin receptor Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 2
- 241000883306 Huso huso Species 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 208000032912 Local swelling Diseases 0.000 description 2
- 101710132593 Protein E2 Proteins 0.000 description 2
- 101710132594 Protein E6 Proteins 0.000 description 2
- 101710132595 Protein E7 Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000012623 in vivo measurement Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100028681 C-type lectin domain family 4 member K Human genes 0.000 description 1
- 101710183165 C-type lectin domain family 4 member K Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 210000005236 CD8+ effector T cell Anatomy 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 206010061041 Chlamydial infection Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000986086 Homo sapiens HLA class I histocompatibility antigen, A alpha chain Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- 101100102460 Human papillomavirus type 16 E2 gene Proteins 0.000 description 1
- 101100156155 Human papillomavirus type 16 E7 gene Proteins 0.000 description 1
- 101000622322 Human papillomavirus type 16 Regulatory protein E2 Proteins 0.000 description 1
- 241000341657 Human papillomavirus type 18 Species 0.000 description 1
- 241000701830 Human papillomavirus type 31 Species 0.000 description 1
- 241000701826 Human papillomavirus type 33 Species 0.000 description 1
- 241000701790 Human papillomavirus type 45 Species 0.000 description 1
- 241000722343 Human papillomavirus types Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 101710125507 Integrase/recombinase Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000139306 Platt Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000027526 T cell tolerance induction Effects 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102000008230 Toll-like receptor 3 Human genes 0.000 description 1
- 108010060885 Toll-like receptor 3 Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 208000006842 Tonsillar Neoplasms Diseases 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000009743 cell cycle entry Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000015698 cervical squamous intraepithelial neoplasia Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000000902 chlamydia Diseases 0.000 description 1
- 208000012538 chlamydia trachomatis infectious disease Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003426 epidermal langerhans cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94107007P | 2007-05-31 | 2007-05-31 | |
| EP07109287 | 2007-05-31 | ||
| US60/941,070 | 2007-05-31 | ||
| EP07109287.8 | 2007-05-31 | ||
| PCT/NL2008/050315 WO2009002159A2 (en) | 2007-05-31 | 2008-05-27 | Intradermal hpv peptide vaccination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2688589A1 true CA2688589A1 (en) | 2008-12-31 |
Family
ID=38477016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002688589A Abandoned CA2688589A1 (en) | 2007-05-31 | 2008-05-27 | Intradermal hpv peptide vaccination |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9562075B2 (enExample) |
| EP (1) | EP2155240B1 (enExample) |
| JP (2) | JP2010530362A (enExample) |
| CN (1) | CN101795705A (enExample) |
| AU (1) | AU2008269721B2 (enExample) |
| BR (1) | BRPI0812311A8 (enExample) |
| CA (1) | CA2688589A1 (enExample) |
| ES (1) | ES2482192T3 (enExample) |
| MX (1) | MX2009012922A (enExample) |
| WO (1) | WO2009002159A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008257792B2 (en) * | 2007-05-31 | 2013-08-29 | Isa Pharmaceuticals B.V. | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines |
| EP2344191A4 (en) * | 2008-09-02 | 2013-02-13 | Antigen Express Inc | HUMAN PAPILLOMAVIRUS / LI-KEY HYBRIDS AND METHODS OF USE |
| CA2819416C (en) | 2010-12-02 | 2019-04-30 | Bionor Immuno As | Peptide scaffold design |
| EP2883550A1 (en) * | 2013-12-12 | 2015-06-17 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Novel promiscuous HPV16-derived T helper epitopes for immunotherapy |
| US10934525B2 (en) | 2015-10-30 | 2021-03-02 | Children's National Medical Center | Generating HPV antigen-specific cells from a naive T cell population |
| EP3377099A4 (en) | 2015-11-18 | 2019-07-24 | ImmunoVaccine Technologies Inc. | ADJUVANT SYSTEMS AND WATER-FREE VAPOR COMPOSITION OF ONE POLYI: C-POLYNUCLEOTIDADJUVANS AND ADJUVANS ON LIPID BASE |
| MY201964A (en) * | 2016-06-20 | 2024-03-27 | Isa Pharmaceuticals B V | Formulation of a peptide vaccine |
| WO2019099723A2 (en) * | 2017-11-15 | 2019-05-23 | Arizona Board Of Regents On Behalf Of Arizona State University | Materials and methods relating to immunogenic epitopes from human papillomavirus |
| JP7595827B2 (ja) * | 2018-03-12 | 2024-12-09 | ステムセル テクノロジーズ カナダ インコーポレーテッド | 免疫応答を改変するための生体分子の細胞内送達 |
| PE20201201A1 (es) * | 2018-03-12 | 2020-11-11 | Sqz Biotechnologies Co | Metodos para tratar las enfermedades asociadas al vph |
| WO2019210055A2 (en) * | 2018-04-26 | 2019-10-31 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
| WO2022147442A1 (en) * | 2020-12-29 | 2022-07-07 | Sqz Biotechnologies Company | Formulations of activating antigen carriers |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4777239A (en) * | 1986-07-10 | 1988-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic peptides of human papilloma virus |
| US5180806A (en) * | 1988-05-16 | 1993-01-19 | The Scripps Research Institute | Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods |
| US5932412A (en) | 1990-05-11 | 1999-08-03 | Euro-Diagnostica Ab | Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes |
| DE9106105U1 (de) * | 1991-05-17 | 1991-09-26 | Behringwerke Ag, 3550 Marburg | Diagnose-Kit zum Nachweis von Human-Papillomavirusinfektionen |
| US6419931B1 (en) | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
| GB9505784D0 (en) * | 1995-03-22 | 1995-05-10 | Lynxvale Ltd | Anti-tumour treatment |
| AU721927B2 (en) | 1995-12-22 | 2000-07-20 | Immunomedics Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
| ES2330017T3 (es) | 1998-05-23 | 2009-12-03 | Leiden University Medical Center | Ligandos de cd40 y peptidos de ctl para tratar tumores. |
| US20030118588A1 (en) | 1999-05-22 | 2003-06-26 | Linda Diehl | Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40 |
| US6641994B2 (en) * | 1999-08-25 | 2003-11-04 | Pharmacia & Upjohn Company | Methods of identifying anti-viral agents |
| US20020044948A1 (en) * | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| ES2519043T3 (es) * | 2000-12-08 | 2014-11-06 | Academisch Ziekenhuis Leiden | Péptidos largos de 22-45 residuos de aminoácidos que inducen y/o mejoran las respuestas inmunológicas específicas para antígenos |
| WO2003008649A1 (en) * | 2001-07-20 | 2003-01-30 | Board Of Regents, The University Of Texas System | Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin |
| US6884605B2 (en) * | 2001-08-09 | 2005-04-26 | Board Of Trustees Of The University Of Arkansas | Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer |
| AU2004308964B2 (en) | 2003-12-23 | 2010-09-16 | Arbor Vita Corporation | Antibodies for oncogenic strains of HPV and methods of their use |
| EP1699479A1 (en) * | 2003-12-24 | 2006-09-13 | Leiden University Medical Center | Synthetic protein as tumor-specific vaccine |
| US8252893B2 (en) | 2005-01-31 | 2012-08-28 | Board Of Trustees Of The University Of Arkansas | CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof |
| DE602006021408D1 (de) * | 2005-04-27 | 2011-06-01 | Univ Leiden Medical Ct | Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
-
2008
- 2008-05-27 MX MX2009012922A patent/MX2009012922A/es active IP Right Grant
- 2008-05-27 JP JP2010510239A patent/JP2010530362A/ja active Pending
- 2008-05-27 CN CN200880101172A patent/CN101795705A/zh active Pending
- 2008-05-27 ES ES08753797.3T patent/ES2482192T3/es active Active
- 2008-05-27 EP EP08753797.3A patent/EP2155240B1/en not_active Not-in-force
- 2008-05-27 CA CA002688589A patent/CA2688589A1/en not_active Abandoned
- 2008-05-27 US US12/451,983 patent/US9562075B2/en not_active Expired - Fee Related
- 2008-05-27 BR BRPI0812311A patent/BRPI0812311A8/pt not_active IP Right Cessation
- 2008-05-27 WO PCT/NL2008/050315 patent/WO2009002159A2/en not_active Ceased
- 2008-05-27 AU AU2008269721A patent/AU2008269721B2/en not_active Ceased
-
2014
- 2014-06-27 JP JP2014133168A patent/JP5888823B2/ja not_active Expired - Fee Related
-
2016
- 2016-12-16 US US15/381,367 patent/US20170143818A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008269721B2 (en) | 2013-01-10 |
| AU2008269721A1 (en) | 2008-12-31 |
| US20100196353A1 (en) | 2010-08-05 |
| US20170143818A1 (en) | 2017-05-25 |
| BRPI0812311A8 (pt) | 2019-02-05 |
| US9562075B2 (en) | 2017-02-07 |
| CN101795705A (zh) | 2010-08-04 |
| WO2009002159A2 (en) | 2008-12-31 |
| JP5888823B2 (ja) | 2016-03-22 |
| JP2014185179A (ja) | 2014-10-02 |
| JP2010530362A (ja) | 2010-09-09 |
| EP2155240B1 (en) | 2014-04-30 |
| WO2009002159A3 (en) | 2009-02-12 |
| BRPI0812311A2 (pt) | 2014-10-29 |
| ES2482192T3 (es) | 2014-08-01 |
| MX2009012922A (es) | 2010-07-05 |
| EP2155240A2 (en) | 2010-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11458198B2 (en) | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines | |
| AU2008269721B2 (en) | Intradermal HPV peptide vaccination | |
| AU2013205259B2 (en) | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines | |
| AU2015213420B2 (en) | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines | |
| HK40019593A (en) | Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130426 |
|
| FZDE | Dead |
Effective date: 20190528 |